Also listed on Novartis Institutes for Biomedical Research, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Jan 30, 2035 · High confidence
20-year base term ends Jan 30, 2035
Held by Novartis AG
Filed Feb 14, 2017 as application 15/432,819 · Granted Nov 12, 2019
Base term, 20 years from filing
Today
2015
2035
Clock starts
Jan 30, 2015
Jan 30, 2015
Term ends
Jan 30, 2035
Jan 30, 2035
Granted
Nov 12, 2019
Nov 12, 2019
base term
fee events
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
6
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. 1 of 3 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jan 30, 2015, when application 14/610,837, the earliest non-provisional in its chain, was filed (this one was filed Feb 14, 2017) | Jan 30, 2035 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jan 30, 2035 | High confidence |
This family
| US 9,605,070 | In force Jan 2035 | Jan 2035 |
| US 10,472,419 | this patent Jan 2035 | Jan 2035 |
| US 9,884,913 | In force Jan 2035 | Jan 2035 |
| US 11,155,620 | In force Feb 2035 | Feb 2035 |
| US 10,981,990 | In force Jan 2035 | Jan 2035 |
| Application 17/484,794 | Abandoned not computed | not computed |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Dec 21, 2017 Reel 44467, frame 158 | Sabatos-peyton, Catherine Anne; Mataraza, Jennifer Marie; Blattler, Walter A.; Hicklin, Daniel J. | Costim Pharmaceuticals Inc. | Assignment of Assignor's Interest |
| Dec 21, 2017 Reel 44467, frame 177 | Freeman, Gordon James | Dana-Farber Cancer Institute, Inc. | Assignment of Assignor's Interest |
| Dec 21, 2017 Reel 44467, frame 186 | Dekruyff, Rosemarie H.; Umetsu, Dale T. | Children's Medical Center Corporation | Assignment of Assignor's Interest |
| Dec 21, 2017 Reel 44467, frame 197 | Brannetti, Barbara; Huber, Thomas; Pietzonka, Thomas | Novartis Pharma AG | Assignment of Assignor's Interest |
| Dec 21, 2017 Reel 44467, frame 205 | Vasquez, Maximiliano | Galaxy Biotech, LLC | Assignment of Assignor's Interest |
| Dec 21, 2017 Reel 44467, frame 210 | Harris, Alan S. | Novartis Institutes for Biomedical Research, Inc. | Assignment of Assignor's Interest |
| Dec 21, 2017 Reel 44467, frame 218 | Galaxy Biotech, LLC | Costim Pharmaceuticals Inc. | Assignment of Assignor's Interest |
| Dec 21, 2017 Reel 44467, frame 230 | Costim Pharmaceuticals Inc. | Novartis AG | Assignment of Assignor's Interest |
| Dec 21, 2017 Reel 44467, frame 256 | Novartis Pharma AG | Novartis AG | Assignment of Assignor's Interest |
| Dec 21, 2017 Reel 44467, frame 265 | Novartis Institutes for Biomedical Research, Inc. | Novartis AG | Assignment of Assignor's Interest |
| Dec 22, 2017 Reel 44467, frame 962 | Hu, Tiancen; Taraszka, John A.; Xu, Fangmin | Novartis Institutes for Biomedical Research, Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jan 2035
Term ends Jan 30, 2035. Maintenance fees still fall due before then
Citations
25
later US patents cite this one
That is top 10% of utility patents granted in 2019 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.